Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Arch Gynecol Obstet ; 306(5): 1761-1769, 2022 11.
Article in English | MEDLINE | ID: mdl-35987819

ABSTRACT

PURPOSE: We prospectively investigated if oral enteric coating lactoferrin supplementation improves the reproductive outcomes in infertile women with a history of repeated implantation failure (RIF) and non-Lactobacillus-dominant (Lactobacillus rate < 90%) microbiota (NLDM) in vaginal secretions (VS)/endometrial fluid (EF). METHODS: Paired VS/EF samples were obtained from RIF women and control infertile women (non-RIF group) for microbiome analysis. Chronic endometritis (CE) was diagnosed histopathologically and hysteroscopically. In a pilot study, oral enteric coating lactoferrin (700 mg/day, at least 28 consecutive days) was administered to eligible patients with NLDM in VS/EF. Their reproductive outcomes in the subsequent vitrified-warmed embryo transfer cycles were followed up. RESULTS: While CE was more prevalent (OR 2.41, 95% CI 1.02-5.63, p = 0.042) in the RIF group (29.1%, n = 117) than in the non-RIF group (14.5%, n = 55), The NLDM rate was similar between the two groups (44.4 vs 52.7%). Lactoferrin supplementation improved NLDM in 43.2% of RIF women (n = 37). Within the RIF group, the live birth rate in the subsequent cycles was higher (OR 10.67, 95% CI 1.03 - 110.0, p = 0.046) in women with improved microbiota (57.1%, n = 14) than in those with unimproved microbiota (11.1%, n = 9). CONCLUSION: Unlike CE, NLDM was not unique to RIF but was common in infertile women. Although the therapeutic effect of the oral lactoferrin supplementation on NLDM was limited in a pilot study, the reproductive outcomes were better in RIF women who overcame NLDM than in those who failed. Randomized controlled trials are required to confirm the results. TRIAL REGISTRATION NUMBER AND DATE FOR PROSPECTIVELY REGISTERED TRIALS: UMIN-CTR 000036990, June 7, 2019.


Subject(s)
Endometritis , Infertility, Female , Dietary Supplements , Dysbiosis , Embryo Implantation , Endometrium , Female , Humans , Infertility, Female/therapy , Lactoferrin/therapeutic use , Live Birth , Pilot Projects , Pregnancy
2.
Pharm Dev Technol ; 26(9): 1010-1020, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34412566

ABSTRACT

This work focuses on the extrusion of a brittle, tacky, cationic copolymer i.e. Eudragit® E-100 to prepare filament and subsequent 3D printing of hollow capsular device using the extruded filament. An optimum amount of talc and triethyl citrate was used for the possible extrusion of the polymer. There was no thermal and chemical degradation of the polymer observed after extrusion confirmed by DSC and FTIR analysis. Microscopic analysis of the printed capsule showed the layer-by-layer manner of 3D printing. Capsule parts were printed according to the set dimensions (00 size) with minimal deviation. Printed capsule showed the soluble behaviour in gastric fluid pH 1.2 where within 15 min the encapsulated drug encounters with the dissolution medium and almost 70% drug was dissolved within 4 hr. In case of phosphate buffer pH 6.8, the printed capsule showed a longed swelling behaviour up to 12 hr and then gradually bursting of capsule occurred wherein more than 90% encapsulated drug was dissolved within 36 hr. Enteric coating of the printed capsule showed similar behaviour in alkaline medium that observed with non-enteric capsule. This indicates the potential application of this printed capsules for both gastric and intestinal specific delayed drug delivery by a single step enteric coating process.


Subject(s)
Acrylates/chemical synthesis , Acrylates/pharmacokinetics , Chemistry, Pharmaceutical/methods , Polymers/chemical synthesis , Polymers/pharmacokinetics , Printing, Three-Dimensional , Berberine/chemical synthesis , Berberine/pharmacokinetics , Capsules , Delayed-Action Preparations/chemical synthesis , Delayed-Action Preparations/pharmacokinetics , Drug Evaluation, Preclinical/methods , Drug Liberation , Tablets, Enteric-Coated
3.
Pharm Dev Technol ; 24(10): 1210-1217, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31354006

ABSTRACT

The objective of this study was to investigate the efficiency of moisture protection of hot-melt coatings solely and in combination with an enteric coating on hygroscopic tablet cores containing a spray-dried Sennae fructus extract. Tablet cores were subcoated with different hot-melt coating materials: medium chain tryglycerides, stearic acid, Precirol® ATO 5, and Compritol® 888 ATO, at varying amounts and coated with Eudragit® L 30D-55 for enteric resistance. Subcoating penetration, tablet disintegration, dissolution times, tablet hygroscopicity, and tablet properties such as weight, height, diameter, and hardness were analyzed. 3 mg/cm2 of tablet surface seemed to be sufficient if sustained release is not required. Thereby, hot-melt coating did not adversely affect the tablet properties with regard to subsequent processing steps. Compared to the tablet cores it was possible to reduce the moisture uptake by 85% at 75% relative humidity with tablets coated with a combination of Precirol® ATO 5 and Eudragit® L 30D-55. This combination was more efficient than high amounts of Eudragit® L 30D-55. Hot-melt coating proved to be a suitable technique for the application of subcoating material to tablet cores serving as a barrier against water permeation into hygroscopic tablet cores without exceeding the required disintegration times.


Subject(s)
Drug Compounding/methods , Laxatives/chemistry , Polymethacrylic Acids/chemistry , Senna Extract/chemistry , Chemistry, Pharmaceutical , Drug Liberation , Solubility , Surface Properties , Tablets, Enteric-Coated , Wettability
4.
J Dairy Sci ; 102(8): 6959-6970, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31255265

ABSTRACT

In this paper, we report the physicochemical and sensory properties of milk supplemented with a powder of microencapsulated lactase. The core material was lactase (ß-galactosidase), the primary coating material was medium-chain triglyceride (MCT), and the secondary (enteric) coating material was either hydroxypropyl methylcellulose phthalate (HPMCP) or shellac, comparing both against market milk as a control. The physicochemical properties of both types of microcapsules were analyzed, including the particle size, zeta potential, and in vitro release behavior. To survey the stability of the microcapsules in milk during storage, we studied the residual lactose content and pH. Furthermore, to determine the properties of milk supplemented with the microcapsules, changes in color and sensory properties were evaluated during storage. The particle sizes (volume-weighted mean; D[4,3]) of the microcapsules coated with HPMCP or shellac were 2,836 and 7,834 nm, respectively, and the zeta potential of the capsules coated with shellac was higher than the zeta potential of those coated with HPMCP. The pH levels of milk supplemented with the lactase microcapsules were similar to those of the control (unsupplemented market milk); however, for milk supplemented with HPMCP-coated microcapsules, the pH was slightly lower. The core material, lactase, was released from the microcapsules during 12-d storage, and 18.82 and 35.09% of lactose was hydrolyzed in the samples for HPMCP- and shellac-coated microcapsules, respectively. The sensory characteristics of milk containing microcapsules coated with HPMCP did not show significant differences from the control, in terms of sweetness or off-taste, until 8 d of storage. However, shellac-coated microcapsules showed significant difference in sweetness and off-taste at d 8 and 6 of storage, respectively. The color of milk containing HPMCP-coated microcapsules did not show a significant difference during storage. However, that containing shellac-coated microcapsules was somewhat higher in color values than others. In particular, it showed significance from 0 to 4 d storage in L* and C* values. In conclusion, a powder of lactase microcapsules coated with HPMCP can be suitable as a supplement for milk.


Subject(s)
Dietary Supplements , Kluyveromyces/enzymology , Lactase/administration & dosage , Methylcellulose/analogs & derivatives , Milk/chemistry , Animals , Capsules , Chemical Phenomena , Drug Compounding/veterinary , Fungal Proteins/administration & dosage , Hydrolysis , Lactose/metabolism , Methylcellulose/chemistry , Milk/metabolism , Particle Size , Powders , Resins, Plant/chemistry , Taste , Triglycerides/chemistry
5.
J Microencapsul ; 33(2): 183-90, 2016.
Article in English | MEDLINE | ID: mdl-26878684

ABSTRACT

The hypothesis was that green tea catechins (GTCs) formulated with vitamin C and xylitol followed by enteric coating with hydroxypropyl methyl cellulose phthalate (HPMCP) or encapsulated into γ-cyclodextrin (γ-CD) could enhance intestinal absorption of GTCs. Surface morphology and size obtained by SEM were different. Digestive stability of GTCs encapsulated into γ-CD or coated with HPMCP was enhanced up to 65.56% or 57.63%, respectively. When GTCs were formulated, the digestive stability was greater than the one not formulated. Formulated GTCs followed by encapsulation into γ-CD significantly increased intestinal transport. Absorption of GTCs was 2.8%, 9.64%, 11.97%, 8.41% and 14.36% for only GTCs, GTCs encapsulated into γ-CD, formulated GTCs encapsulated into γ-CD, GTCs coated with HPMCP and formulated GTCs coated with HPMCP, respectively. This study suggests that GTCs, formulated with vitamin C and xylitol followed by γ-CD encapsulation or HPMCP enteric coating, provide combinational effect to increase bioavailability of GTCs.


Subject(s)
Catechin/administration & dosage , Catechin/pharmacokinetics , Drug Carriers/chemistry , Methylcellulose/analogs & derivatives , gamma-Cyclodextrins/chemistry , Caco-2 Cells , Catechin/chemistry , Catechin/metabolism , Digestion , Humans , Intestinal Absorption , Methylcellulose/chemistry , Tablets, Enteric-Coated , Tea/chemistry
6.
J Pharm Sci ; 105(2): 509-511, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26523769

ABSTRACT

To investigate the effect of calcium ions on the disintegration of enteric-coated dosage forms, disintegration testing was performed on enteric-coated aspirin tablets in the presence and absence of calcium in the test media. The results show that the presence of calcium ions retards the disintegration of enteric-coated dosage forms. This finding, which has not been reported in scientific literature, sheds light on the importance of conducting well-designed detailed investigations into the potential of calcium from dietary sources, calcium supplements, antacids, and/or phosphate binders affecting the absorption of drugs formulated into enteric-coated dosage forms. Moreover, it shows the necessity to investigate the potential of the occurrence of additional nutrient-excipient interactions.


Subject(s)
Calcium Chloride/chemistry , Calcium Chloride/metabolism , Tablets, Enteric-Coated/chemistry , Tablets, Enteric-Coated/metabolism , Aspirin/chemistry , Aspirin/metabolism , Dosage Forms , Drug Liberation , Solubility
7.
Mol Cell Biochem ; 408(1-2): 73-87, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26152904

ABSTRACT

In this study, we evaluated the effects of Korean mistletoe (Viscum album L. var. coloratum) coated with a biodegradable polymer (Eudragit(®)) wall on the growth of mouse melanoma in vivo. Oral administration of 4% (430 mg/kg/day) enteric-coated mistletoe resulted in a significant reduction in tumor volume on day 14 compared to the negative control group in B16F10 melanoma-inoculated BDF1 mice. When we measured the survival rate, enteric-coated mistletoe-received mice had a higher survival rate after day 12. Also, we investigated the mechanism involving the cancer cell growth inhibition when melanoma cells were treated with Korean mistletoe lectin (Viscum album L. var. coloratum agglutinin, VCA) and its extract in vitro. As a result, a significant G0/G1 arrest was observed in both B16BL6 and B16F10 melanoma cells with VCA or mistletoe extract. In addition, VCA or mistletoe extract induced an increase in both early and late apoptosis in cells. When we studied the molecular mechanism, our results showed that VCA and mistletoe extract can increase activated multiple caspases (caspase-1, 3, 4, 5, 6, 7, 8, and 9), dose-dependently. We also found out that VCA and mistletoe treatment causes a significant decrease in the expression of procaspase-3 and 8.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Melanoma, Experimental/drug therapy , Mistletoe/metabolism , Plant Lectins/administration & dosage , Ribosome Inactivating Proteins/administration & dosage , Skin Neoplasms/drug therapy , Administration, Oral , Animals , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis , Caspase 3/metabolism , Caspase 8/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Drug Screening Assays, Antitumor , Gene Expression Regulation, Neoplastic/drug effects , In Vitro Techniques , Melanoma, Experimental/metabolism , Mice , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Plant Lectins/chemistry , Plant Lectins/pharmacology , Polymers/chemistry , Ribosome Inactivating Proteins/chemistry , Ribosome Inactivating Proteins/pharmacology , Skin Neoplasms/metabolism , Survival Analysis
8.
Int J Pharm ; 456(2): 569-71, 2013 Nov 18.
Article in English | MEDLINE | ID: mdl-23994758

ABSTRACT

The aim of the study is to present the concept of novel method for fast screening of enteric coating compositions properties without the need of preparation of tablets batches for fluid bed coating. Proposed method involves evaluation of enteric coated model tablets in specially designed testing cell with application of MRI technique. The results obtained in the testing cell were compared with results of dissolution studies of mini-tablets coated in fluid bed apparatus. The method could be useful in early stage of formulation development for screening of film coating properties that will shorten and simplify the development works.


Subject(s)
Chemistry, Pharmaceutical/methods , Magnetic Resonance Imaging/methods , Tablets, Enteric-Coated/chemistry , Drug Evaluation, Preclinical/methods
SELECTION OF CITATIONS
SEARCH DETAIL